Trials / Completed
CompletedNCT01163487
Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
Phase I Trial of Metabolic Reprogramming Therapy for Treatment of Recurrent Head and Neck Cancers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Daniel T. Chang · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to study the effect of the drug DCA (dichloroacetate) on recurrent head and neck cancers. Part of this study will also use EF5 PET scan to study tumor hypoxia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dichloroacetate | 25-50mg/kg per day; oral |
| DEVICE | EF5 | 21 mg/kg; IV |
Timeline
- Start date
- 2010-08-01
- Primary completion
- 2015-02-01
- Completion
- 2016-02-01
- First posted
- 2010-07-15
- Last updated
- 2022-06-16
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01163487. Inclusion in this directory is not an endorsement.